Vignesh Packiam, Associate Professor at Rutgers Cancer Institute of New Jersey, shared a post by European Urology Oncology on X, adding:
“I like this paper. Two interesting findings:
- LVI is rare but important.. corroborates we found Ryan Werntz.
LVI is one of the worst risk factors… T1 with LVI is worse than T2 without it… Need to be more flexible in considering NAC for these patients
- Outcomes did not differ by stage (Ta vs CIS vs T1). To me this corroborates paradigm shift illustrated by JCOG1019… my interpretation is that thorough/excellent TURBT can trump specific NMIBC stage”
Quoting European Urology Oncology’s post:
“Latest Article Online!
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients by Mehdi Kardoust Parizi…Shahrokh F. Shariat et al
Thank you to the authors for trusting EUO with your work!”
Title: Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients
Authors: Mehdi Kardoust Parizi, David D’Andrea, Benjamin Prader, Jeremy Yuen-Chun Teo, Piotr Chłosta, Pierre I. Karakiewicz, Ekaterina Laukhtina, Marco Moschini, Mohammad Abufaraj, Dmitry Enikeev, Leonardo Oliveira Reis, Katherina Oberneder, Stephan Brönimann, Marcin Miszczyk, Shahrokh F. Shariat.
Other articles about GU Oncology on OncoDaily.
